The FRAX® as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study
The World Health Organization Fracture Risk Assessment Tool (FRAX®) was recently developed to estimate the 10-year absolute risk of osteoporotic fracture among the general population. However, the evidence for its use in chronic kidney disease patients has been lacking, and the association between the FRAX® and mortality is unknown. Therefore, a hospital-based, prospective, cohort study was conducted to evaluate the predictive ability of the FRAX® for mortality in hemodialysis patients. A total of 252 patients who had been started on maintenance hemodialysis, 171 men and 81 women, with a mean age of 67 ± 14 years, was studied. The endpoint was defined as all-cause death. The Cox proportional hazards model was used to calculate hazard ratios and 95 % confidence intervals. During the mean follow-up period of 3.4 ± 2.7 years, 61 deaths occurred. The median (interquartile range) of the FRAX® for major osteoporotic fracture was 6.9 (4.6–12.0) % in men and 19.0 (7.6–33.0) % in women. Cumulative survival rates at 5 years after starting dialysis, with the FRAX® levels above and below the median, were 51.9 and 87.9 %, respectively, in men and 67.4 and 83.7 %, respectively, in women. Overall, in men, the multivariate Cox regression analyses revealed that the log-transformed FRAX® remained an independent predictor of death after adjusting by confounding variables. However, in women, the significant association between the FRAX® value and the outcome was eliminated if age was put into these models. Among Japanese hemodialysis patients, the FRAX® seems to be useful for predicting death, especially in men.
KeywordsCKD FRAX Hemodialysis Mortality
There are no potential conflicts of interest relevant to this article to report. Parts of this study were presented in abstract form at the Annual Meeting of ASN, Nov 5-10, 2013, Atlanta, Georgia, USA.
Conflict of interest
All authors have no conflicts of interest to declare in connection with this paper.
- 5.Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358–1366CrossRefPubMedGoogle Scholar
- 7.White BL, Fisher WD, Laurin CA (1987) Rate of mortality for elderly patients after fracture of the hip in the 1980’s. J Bone Jt Surg Am 69:1335–1340Google Scholar
- 12.Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526CrossRefGoogle Scholar
- 16.Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T, CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17:247–288CrossRefPubMedGoogle Scholar
- 17.Moroi M, Tamaki N, Nishimura M, Haze K, Nishimura T, Kusano E, Akiba T, Sugimoto T, Hase H, Hara K, Nakata T, Kumita S, Nagai Y, Hashimoto A, Momose M, Miyakoda K, Hasebe N, Kikuchi K (2013) Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis: results from a cohort study in Japan. Am J Kidney Dis 61:466–475CrossRefPubMedGoogle Scholar
- 24.Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K (1996) Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 94:1175–1192CrossRefPubMedGoogle Scholar
- 30.Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the FRAX Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRefGoogle Scholar